{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:54:22Z","timestamp":1791266062251,"version":"4.1.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:00:00Z","timestamp":1791244800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have become the standard treatment for patients with advanced microsatellite instability-high (MSI-H) gastric cancer. However, the incidence of immune-related adverse events (irAEs) has also increased accordingly. Immune-related colitis (IRC) is among the most common gastrointestinal manifestations of these irAEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>This report describes a patient with advanced MSI-H gastric cancer who received immunotherapy and developed Grade-3 IRC during treatment. The patient recovered following corticosteroid therapy. Diarrhea recurred after discontinuation of corticosteroids, a condition that may be misdiagnosed as a recurrence of IRC. Following a multidisciplinary team consultation, the patient was clinically diagnosed with Clostridioides difficile infection (CDI) based on symptoms and stool testing, and showed rapid improvement after vancomycin therapy. The patient achieved a durable complete clinical response lasting more than 5 years without further systemic anticancer therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This case illustrates that immunotherapy may confer long-term benefit in MSI-H advanced gastric cancer. Notably, the occurrence of immune-related adverse events coincided with sustained tumor control, suggesting a potential association that merits further exploration. However, when diarrhea recurs after discontinuation of corticosteroids, clinicians must remain highly vigilant regarding the overlap and differentiation between the reactivation of IRC and infectious colitis, the involvement of a multidisciplinary team is particularly crucial.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1914463","type":"journal-article","created":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:21:41Z","timestamp":1791264101000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: Immune-related colitis complicated by Clostridioides difficile-associated colitis"],"prefix":"10.3389","volume":"17","author":[{"given":"Wenjuan","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanqian","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaoqun","family":"Sun","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiujuan","family":"Qu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Anticancer Drugs and Biotherapy of Liaoning Province, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Liaoning Province Clinical Research Center for Cancer, The First Hospital of China Medical University","place":["Shenyang, China"]},{"name":"Key Laboratory of Precision Diagnosis and Treatment of Gastrointestinal Tumors, Ministry of Education, The First Hospital of China Medical University","place":["Shenyang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21657","article-title":"Current treatment and recent progress in gastric cancer","volume":"71","author":"Joshi","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12516","article-title":"The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023","volume":"44","author":"Wang","year":"2024","journal-title":"Cancer Commun (London England)"},{"key":"B3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1001\/jamaoncol.2021.0275","article-title":"Assessment of pembrolizumab therapy for the treatment of microsatellite instability\u2013high gastric or gastroesophageal junction cancer among patients in the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials","volume":"7","author":"Chao","year":"2021","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-24-02463","article-title":"Phase II study (NO LIMIT, WJOG13320G) of first-line nivolumab plus low-dose ipilimumab for microsatellite instability-high advanced gastric or esophagogastric junction cancer","volume":"43","author":"Kawakami","year":"2025","journal-title":"J Clin Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmorw.2025.100676","article-title":"Prognostic impact of clinical factors in MSI-H\/dMMR gastrointestinal tumors treated with immune checkpoint inhibitors: Results from a multicenter real-world study","volume":"11","author":"Martinez-Lago","year":"2026","journal-title":"Esmo Real World Data Digit Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447021","article-title":"Toxicity in the era of immune checkpoint inhibitor therapy","volume":"15","author":"Keam","year":"2024","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102440","article-title":"Immune checkpoint inhibitor\u2013induced diarrhea and colitis: Incidence and management. A systematic review and meta-analysis","volume":"109","author":"Nielsen","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009742","article-title":"Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events","volume":"12","author":"Shatila","year":"2024","journal-title":"J Immunother Cancer"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.7355","article-title":"Management and outcomes of Clostridioides difficile infection in patients on immune checkpoint inhibitors","volume":"23","author":"Magahis","year":"2025","journal-title":"J Natl Compr Cancer Network"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.875974","article-title":"Overview of checkpoint inhibitors mechanism of action: Role of immune-related adverse events and their treatment on progression of underlying cancer","volume":"9","author":"Iranzo","year":"2022","journal-title":"Front Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S243787","article-title":"A first-in-human dose finding study of camrelizumab in patients with advanced or metastatic cancer in Australia","volume":"14","author":"Lickliter","year":"2020","journal-title":"Drug Des Dev Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2024.09.009","article-title":"Immune-mediated colitis after immune checkpoint inhibitor therapy","volume":"31","author":"Giesler","year":"2025","journal-title":"Trends Mol Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.cmi.2021.09.038","article-title":"European Society of Clinical Microbiology and Infectious Diseases: 2021 update on the treatment guidance document for Clostridioides difficile infection in adults","volume":"27","author":"van Prehn","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciab549","article-title":"Clinical practice guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 focused update guidelines on management of Clostridioides difficile infection in adults","volume":"73","author":"Johnson","year":"2021","journal-title":"Clin Infect Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i1.310","article-title":"S-1-based combination therapy vs S-1 monotherapy in advanced gastric cancer: A meta-analysis","volume":"20","author":"Liu","year":"2014","journal-title":"Wjg"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad474","article-title":"Unintended consequences: Risk of opportunistic infections associated with long-term glucocorticoid therapies in adults","volume":"78","author":"Chastain","year":"2024","journal-title":"Clin Infect Dis Off Publ Infect Dis Soc Am"},{"key":"B18","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1038\/s41467-021-22269-y","article-title":"Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics","volume":"12","author":"van Werkhoven","year":"2021","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1408755","article-title":"Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: A meta-analysis","volume":"14","author":"Zhang","year":"2024","journal-title":"Front Oncol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1186\/s12885-025-13566-6","article-title":"Organ-specific immune-related adverse events and prognosis in cancer patients receiving immune checkpoint inhibitors","volume":"25","author":"Han","year":"2025","journal-title":"BMC Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914463\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T05:21:45Z","timestamp":1791264105000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1914463\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,6]]},"references-count":20,"alternative-id":["10.3389\/fimmu.2026.1914463"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1914463","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,6]]},"article-number":"1914463"}}